Khloris Biosciences, Inc.
About Khloris Biosciences, Inc.
Pioneering Cancer Vaccination Defining the Future of Cancer and Cardiovascular Medicine
Khloris is the first and only company to develop an iPSC-derived whole cell vaccine for the treatment of cancer. Fundamentally differentiated from previous cancer vaccinations, iPSC vaccination combines key mechanistic elements to boost anti-tumor immunity. Presenting a broad spectrum of oncofetal and other cancer-related antigens, iPSC vaccination fully mobilizes the immune system.
Khloris is also developing iPSC-derived cardiomyocytes as a novel cell therapy treatment for patients with cardiovascular diseases.
1 article with Khloris Biosciences, Inc.
-
Leaps by Bayer and Khloris join forces to develop induced pluripotent stem cells (iPSCs) as breakthrough anti-cancer vaccines
4/2/2019
Leaps by Bayer, the investment arm of the global life sciences company Bayer, and Khloris Biosciences, a biotechnology company, announced today that they have joined forces to develop novel, first-in-class anti-cancer vaccines based on human induced pluripotent stem cells (iPSCs).